Why do some people treated for psoriatic arthritis
stop responding to their treatment? Find out next.
Study Confirms High Prevalence of ADA in Adalimumab-Treated Psoriasis
Dr. Graeme M. Lipper, writing in Medscape described a recent study that might shed light
on why some treatments for psoriatic arthritis may fail over time.
Menting, Lumig, DeVries and colleagues published the results of a recent study entitled
Extent and Consequences of Antibody Formation Against Adalimumab in Patients With Psoriasis:
One-Year Follow-up Adalimumab, a humanized monoclonal antibody
(IgG1) that binds to and inactivates the proinflammatory cytokine tumor necrosis factor alpha, is a
highly effective treatment for moderate to severe psoriatic arthritis. Unfortunately,
this drug may induce antidrug antibodies (ADAs) in almost one half of patients taking adalimumab
long-term, and prior studies show that ADAs contribute to disease relapse and waning therapeutic
response to adalimumab and other biologic therapies.
In their study they found that 49 % of patients developed ADAs, with the vast majority (90%)
forming antibody titers within the first 24 weeks of therapy.
Comment: Interesting and answers a lot of questions about failing therapy.